

ANTEO COLLABORATES WITH AXXIN ON DIAGNOSTIC DELIVERY SYSTEM

25 September 2019

Surface chemistry and coating Company Anteo Diagnostics Limited (ASX: ADO) (“Anteo” or “the Company”) is pleased to announce a new non-binding collaboration with globally respected biomedical diagnostic instrumentation company Axxin (www.axxin.com).

Axxin has developed its unique Axxin Cubic™ platform technology that enables low cost, high sensitivity hand held and bench top readers capable of delivering complex test sequences in a wide variety of applications. The company's products are used worldwide in research and development and diagnostic applications. Axxin's technology is used for lateral flow and molecular quantitative assays and tests.

Axxin has established itself as an early leader in commercialising diagnostic delivery systems in partnership with leading biomedical and pharmaceutical companies with Anteo now joining these ranks.

Under the collaboration agreement, Axxin will supply their latest Gen 3 readers to Anteo which will then develop a model assay using AnteoBind™ for use on the reader. Collaboration results will then be published and jointly distributed and marketed to the global Point of Care (PoC) industry.

The success of the collaboration is expected to open up opportunities for Anteo and Axxin and their respective customers. The collaboration has the potential to offer the PoC industry an end-to-end quantitative lateral flow testing solution utilising Anteo's model lateral flow assays and Axxin's point of care reader.

Anteo's Chief Executive Officer Derek Thomson commented, “This is an important and fortuitous collaboration for Anteo as Axxin are based in Australia and have a set of products that provide direct and uncompromised synergy with our PoC strategy. We reported recently that Anteo's collaborations in the Life Sciences sector are ramping up and this latest development with Axxin is one such example. Axxin is a highly respected Australian company with world class products. They recognise the commercial value that AnteoBind™ offers them and the market appeal that an end-to-end product solution will have for the PoC industry. These are the types of collaborations we like, where commercial interests are aligned at the outset.”

“Our overall pipeline in both the Life Sciences and Battery industries is in excellent shape and I look forward to providing further context on this very soon. Greater understanding around the make-up of our pipeline is something we look forward to sharing with our investors.”

ABOUT ANTEO GROUP – Anteo Diagnostics Limited (ADO:ASX)

Anteo is a surface chemistry company with Intellectual Property (“IP”) in its core technology product groups AnteoCoat™, AnteoBind™ and AnteoRelease™. The Company's purpose is to create shareholder value by identifying and solving important global industry problems by providing unique value-add solutions for its customers. Customers operate in the life sciences, diagnostics, energy and medical devices markets.

ABOUT AXXIN GROUP

Axxin provides platforms and diagnostic products for biomedical applications that bridge the gap from research to market with world leading innovation, capability and cost effectiveness. The company's goal is to take the cost and complexity out of point of care diagnostics and near patient applications. The company has extensive experience in instrument design, industrial design, sensor technologies and has applied these to molecular and lateral flow applications.

For more information, please contact:

Derek Thomson, Chief Executive Officer, Anteo Diagnostics Limited: +61 7 3219 0085

Ben Jarvis, Six Degrees Investor Relations: +61 (0) 413 150 448

Follow Anteo Diagnostics on Twitter:



<https://twitter.com/AnteoDX> or visit www.anteotech.com